Company intelligence / Profile preview

Polaris Group

Zhunan, Miaoli County, Taiwanpolaris-group.com ↗

Ownership: Private
Employees: ~160
Development stage: Other

Overview

Polaris Group’s lead asset Pegargiminase ("ADI‑PEG 20", trade name ADZODI) is a biologic targeting arginine metabolism. It is in late-stage clinical development for multiple cancers. A rolling BLA submission was made to the US FDA for malignant pleural mesothelioma in November 2024. Three additional Phase III trials are ongoing for glioblastoma, leiomyosarcoma, and hepatocellular carcinoma. The company is preparing for commercialization and seeking global/regional partners. Early results suggest potential benefit as salvage therapy in BRAFi-resistant melanoma as well.

Therapeutic areas: GastroenterologyOncologyEndocrinology
Modalities: BiologicPeptidesSmall molecule
Industry: Biotech

Partnerships

MD Anderson Cancer Center—collaboration on immunotherapy platform

Beyond the preview

Go deeper on Polaris Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polaris Group.

Explore the full profile